Business Wire

  1. Elix And PRISM BioLab Join Forces To Accelerate AI-Driven Drug Discovery For Challenging Protein-Protein Interaction Targets 4/15/2025

    Elix, Inc. (CEO: Shinya Yuki / HQ: Tokyo, hereinafter “Elix”), an AI drug discovery company with the mission of “Rethinking Drug Discovery”, today announced that it has entered into a drug discovery collaboration with PRISM BioLab, Co. Ltd. (CEO: Dai Takehara / HQ: Kanagawa, hereinafter "PRISM BioLab"), effective April 1, 2025.

  2. eGenesis And OrganOx Announce U.S. FDA Clearance Of IND Application For The Treatment Of Patients With Acute-On-Chronic Liver Failure 4/15/2025

    eGenesis, a biotechnology company developing human-compatible engineered organs to treat patients suffering from organ failure, and OrganOx Ltd., a leading organ medical technology company, today announced the U.S. Food & Drug Administration (FDA) has cleared the investigational new drug (IND) application for EGEN-5784, a human-compatible, genetically engineered porcine liver, used in combination with the OrganOx extracorporeal liver cross-circulation (ELC) system, for patients with acute-on-chronic liver failure (ACLF) suffering from decompensated liver function in the intensive care setting.

  3. Signios Bio Launches With AI-Driven Bioinformatics And Advanced Multiomics Platform To Power The Future Of Precision Medicine And Drug Discovery 4/10/2025

    Signios Biosciences ("Signios Bio"), a science-first biotechnology company at the forefront of multiomics and AI-powered bioinformatics, today announced its rebranding from its previous identity as the US based research division of MedGenome Inc.

  4. Tenpoint Therapeutics Ltd. Submits New Drug Application To U.S. FDA For BRIMOCHOL PF For The Treatment Of Presbyopia 4/8/2025

    Tenpoint Therapeutics, Ltd. (“Tenpoint”), a global, clinical-stage biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for BRIMOCHOL PF for the treatment of presbyopia, an age-related near-vision loss condition impacting approximately two billion people globally and 128 million people in the United States.

  5. CytoTronics Launches Neural Application For Pixel, Unleashing High-Throughput Screening Capability In Drug Discovery For Neurological Disease 4/8/2025

    CytoTronics, Inc., a pioneer of semiconductor-based platforms for discovery in cell biology, launched its Neural application for Pixel systems today. A pioneering innovation for neurodegenerative disease and neurotoxicity research, the application enables high-throughput screening for drug discovery at unprecedented scale.

  6. Plex Research Partners With Ginkgo Bioworks On Artificial Intelligence (AI)-Powered Drug Discovery To Identify Novel Disease Mechanisms And Pathways 4/3/2025

    Plex Research, a biotechnology company using autonomous artificial intelligence (AI) to aid in drug discovery, today announced that it is partnering with Ginkgo Datapoints, a service of Ginkgo Bioworks, to use the Plex AI Platform to deepen the understanding of compound treatment mechanisms of action, potentially revealing new therapeutic applications, based on a large perturbation response profiling dataset.

  7. Revvity Signals Software Unveils Unified Data Platform To Accelerate Drug Discovery 4/2/2025

    Today, Revvity, Inc. announced that its software and informatics division, Revvity Signals Software, will launch its Signals One, a unified software platform evolved from the Company's existing research portfolio, designed to streamline data management across the entire drug discovery lifecycle.

  8. MultiOmic Health And Alloy Therapeutics Collaborate To Discover And Develop Renal Tissue-Targeting Drugs 4/2/2025

    MultiOmic Health Limited (“MOH”), an artificial intelligence (AI)-enabled precision medicine discovery company focused on chronic multifactorial diseases, and Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced they have signed a Memorandum of Understanding to jointly discover and develop first-in-class renal tissue-targeting drugs.

  9. Japan Tobacco And D-Wave Announce Quantum Proof-Of-Concept Outperforms Classical Results For LLM Training In Drug Discovery 3/31/2025

    D-Wave Quantum Inc. (“D-Wave” or the “Company”), a leader in quantum computing systems, software, and services, and the pharmaceutical division of Japan Tobacco Inc. (“JT”) today announced the completion of a joint proof-of-concept project that used quantum computing technology and artificial intelligence (AI) in the drug discovery process.

  10. FDA Approves Qfitlia (Fitusiran), The First siRNA (RNAi Therapeutic) For The Treatment Of Hemophilia A Or B 3/28/2025

    Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today highlighted the significance of the U.S. Food and Drug Administration’s (FDA) approval of Qfitlia (fitusiran), the sixth Alnylam-discovered RNAi therapeutic approved in the U.S., and the first and only therapeutic to lower antithrombin (AT), a protein that inhibits blood clotting, with the goal of promoting thrombin generation to rebalance hemostasis and prevent bleeds.